Screener
Bausch + Lomb BLCO Surgical — Acquisitions (Note 5)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Bausch + Lomb’s 10-Q, filed April 30, 2025.
- Filed
- Apr 30, 2025
- Fiscal quarter
- Q1 FY2025
- Calendar quarter
- Q1 2025
- Accession
- 0001860742-25-000008
| (in millions) | Vision Care | Pharmaceuticals | Surgical | Total |
|---|---|---|---|---|
| Balance, January 1, 2024 | $3,556 | $693 | $326 | $4,575 |
| Acquisitions (Note 5) | — | — | 29 | 29 |
| Foreign exchange | (27) | (49) | (5) | (81) |
| Balance, December 31, 2024 | 3,529 | 644 | 350 | 4,523 |
| Acquisitions (Note 5) | — | — | — | — |
| Foreign exchange | 6 | 33 | 5 | 44 |
| Balance, March 31, 2025 | $3,535 | $677 | $355 | $4,567 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's surgical — acquisitions (note 5)?
- Bausch + Lomb (BLCO) reported surgical — acquisitions (note 5) of $0 in Q1 2025.
- What does surgical — acquisitions (note 5) mean?
- Captures the total cash or consideration paid to acquire other businesses or product lines specifically within the surgical division. This metric tracks the company's strategy to expand its surgical portfolio, such as new intraocular lens technologies or surgical equipment. It serves as a primary indicator of external growth investment.
Ask your AI about Bausch + Lomb's surgical — acquisitions (note 5).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude